Inhibitors of human nitric oxide synthase isoforms with the carbamidine moiety as a common structural element.
Identification of potent and selective inhibitors of inducible nitric oxide synthase (NOS) is of great interest because of their therapeutic potential for treatment of diseases mediated by excess production of nitric oxide. We present here a comparison of potency and selectivity for amino acid and nonamino acid based compounds as inhibitors of human inducible, human endothelial constitutive and human neuronal constitutive NOS isoforms. In addition, a novel series of substituted amidines has been identified as NOS inhibitors. 2-Methylthioacetamidine and 2-thienylcarbamidine were the most potent of the series examined with IC50 values of 3.9 and 2.9 microM for human neuronal constitutive NOS. Cyclopropylcarbamidine and 2-thienylcarbamidine were the most potent inhibitors for human inducible NOS with IC50 values of 5.2 and 6.5 microM, respectively. These substituted amidines represent a new class of NOS inhibitors and provide a foundation for potential therapeutic agents.
Department of Inflammatory Diseases Research, G. D. Searle Research and Development, Monsanto Company, St. Louis, MO 63167, USA.
W M
WM
Moore
R K
RK
Webber
K F
KF
Fok
G M
GM
Jerome
C M
CM
Kornmeier
F S
FS
Tjoeng
M G
MG
Currie
D000578:Amidines / Q000737:chemistry; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000737:chemistry*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000578:Amidines; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D019001:Nitric Oxide Synthase